Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma

被引：23

作者：

Fushimi, Chihiro ^{[1
]}

Okamoto, Isaku ^{[2
]}

Matsuki, Takashi ^{[3
]}

Masubuchi, Tatsuo ^{[1
]}

Okada, Takuro ^{[2
]}

Sato, Hiroki ^{[2
]}

Tsukahara, Kiyoaki ^{[2
]}

Kondo, Takahito ^{[4
]}

Yamashita, Taku ^{[3
]}

Hanyu, Kenji ^{[1
,2
]}

Omura, Go ^{[5
]}

Takahashi, Hideaki ^{[6
]}

Tada, Yuichiro ^{[1
]}

Miura, Kouki ^{[1
]}

机构：

[1] Int Univ Hlth & Welf Mita Hosp, Dept Head & Neck Oncol & Surg, Tokyo, Japan

[2] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[3] Kitasato Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Sagamihara, Kanagawa, Japan

[4] Tokyo Med Univ, Hachioji Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Hachioji, Tokyo, Japan

[5] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan

[6] Yokohama City Univ, Sch Med, Dept Head & Neck Surg, Yokohama, Kanagawa, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 09期

关键词：

Salvage chemotherapy; Immune checkpoint inhibitor; nivolumab; head and neck carcinoma; recurrent or metastatic; best supportive care; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PHASE-II; CETUXIMAB; DOCETAXEL; CANCER; PEMBROLIZUMAB; PACLITAXEL; EFFICACY; THERAPY;

D O I：

10.21873/anticanres.14532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RIM HNSCC) has remained challenging. The effect of salvage chemotherapy (SCT) after nivolumab has been identified recently in other cancer types. The aim of this study was to examine the efficacy of SCT after nivolumab treatment in patients with RIM HNSCC. Patients and Methods: A retrospective study was conducted at four institutions in Japan. Fifty-six patients were enrolled in the study. Results: The overall survival (OS) in SCT patients was significantly longer than that in best supportive care (BSC) patients. In the SCT patients, the median OS, median progression-free survival (PFS) and objective response rate (ORR) were 7.3 months, 23 months and 36%, respectively. Prognostic factor for OS and ORR was performance score (PS) and previous radiation, respectively. Conclusion: SCT after nivolumab is associated with better clinical outcomes in patients with RIM HNSCC compared to those receiving BSC.

引用

页码：5277 / 5283

页数：7

共 18 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[4] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J].

Burtness, Barbara ;

Harrington, Kevin J. ;

Greil, Richard ;

Soulieres, Denis ;

Tahara, Makoto ;

de Castro, Gilberto, Jr. ;

Psyrri, Amanda ;

Baste, Neus ;

Neupane, Prakash ;

Bratland, Ase ;

Fuereder, Thorsten ;

Hughes, Brett G. M. ;

Mesia, Ricard ;

Ngamphaiboon, Nuttapong ;

Rordorf, Tamara ;

Ishak, Wan Zamaniah Wan ;

Hong, Ruey-Long ;

Mendoza, Rene Gonzalez ;

Roy, Ananya ;

Zhang, Yayan ;

Gumuscu, Burak ;

Cheng, Jonathan D. ;

Jin, Fan ;

Rischin, Danny .

LANCET, 2019, 394 (10212) :1915-1928

[5] Prognostic impact of hemoglobin levels on treatment outcome in patients with nasopharyngeal carcinoma treated with sequential chemoradiotherapy or radiotherapy alone [J].

Chua, DTT ;

Sham, JST ;

Choy, DTK .

CANCER, 2004, 101 (02) :307-316

[6] Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer [J].

Costantini, Adrien ;

Corny, Jennifer ;

Fallet, Vincent ;

Renet, Sophie ;

Friard, Sylvie ;

Chouaid, Christos ;

Duchemann, Boris ;

Giroux-Leprieur, Etienne ;

Taillade, Laurent ;

Doucet, Ludovic ;

Nguenang, Marina ;

Jouveshomme, Stephane ;

Wislez, Marie ;

Tredaniel, Jean ;

Cadranel, Jacques .

ERJ OPEN RESEARCH, 2018, 4 (02)

[7] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[8] Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors [J].

Fiala, Ondrej ;

Sorejs, Ondrej ;

Sustr, Jan ;

Kucera, Radek ;

Topolcan, Ondrej ;

Finek, Jindrich .

ANTICANCER RESEARCH, 2020, 40 (03) :1219-1227

[9] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck [J].

Hitt, R. ;

Irigoyen, A. ;

Cortes-Funes, H. ;

Grau, J. J. ;

Garcia-Saenz, J. A. ;

Cruz-Hernandez, J. J. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :1016-1022

[10] Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial [J].

Machiels, Jean-Pascal H. ;

Haddad, Robert I. ;

Fayette, Jerome ;

Licitra, Lisa F. ;

Tahara, Makoto ;

Vermorken, Jan B. ;

Clement, Paul M. ;

Gauler, Thomas ;

Cupissol, Didier ;

Jose Grau, Juan ;

Guigay, Joel ;

Caponigro, Francesco ;

de Castro, Gilberto, Jr. ;

Viana, Luciano de Souza ;

Keilholz, Ulrich ;

del Campo, Joseph M. ;

Cong, Xiuyu Julie ;

Ehrnrooth, Eva ;

Cohen, Ezra E. W. .

LANCET ONCOLOGY, 2015, 16 (05) :583-594

← 1 2 →